Yashoda Super Specialty Kaushambi
The Subject Expert Committee of Drugs Controller General of India (DCGI) on Wednesday recommended Serum Institute’s indigenously developed quadrivalent human papillomavirus (qHPV) vaccine for cervical cancer patients.
“An expert panel of India’s central drug authority on Wednesday recommended granting of market authorisation to Serum Institute of India (SII) indigenously-developed India’s first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer”, said a source.
The vaccine has been recommended for cervical cancer patients those above 9 years to 26 years of age for both male and female.According to the source, an application has also been sent to the National Technical Advisory Group on Immunisation (NTAGI).
The NTAGI may take the final decision on the HPV vaccine in the next meeting scheduled to be held on June 29.
Union Health Minister JP Nadda was admitted to AIIMS Delhi following the complaint of breathing…
India has achieved a milestone in organ transplantation, recording its highest-ever number of transplants in…
Mothers Against Vaping (MAV), a collective of mothers worried about the future of their children,…
A parliamentary committee has recommended mandatory kidney function tests every six months for everyone aged…
A parliamentary committee has recommended that a private hospital room in a metropolitan city should…
The Integrated Health & Wellbeing (IHW) Council marked World IVF Day by convening the 7th…